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The growth and differentiation ofB lymphocytes are regulated by complex mech-
anisms that involve the action of cytokines such as IL-1, IL-2, IL-4, IL-5, TNFa
and -0, IFN--y, -a, and -0, low molecular weight B cell growth factor (LMW BCGF),
and high molecular weight BCGF (1, 2). In addition, IL-6/IFN-02/BSF2 is a potent
inducer of Ig secretion in human B cells, and it also has growth factor activity for
hybridomas and plasmacytomas (1, 3). Recent evidence suggests that activated normal
B cells are capable ofsecreting cytokines that are involved in the regulation of growth
and differentiation of B lymphoid cells, such as IL-1, TNFa, and IL-6 (4-6). In
this report we have examined the production of TNFa/(3 and IL-6 by extensively
purified human B lymphocytes activated by different growth stimuli. The combina-
tion ofphorbol esters and the calcium ionophore ionomycin was particularly potent
in inducing the production of these cytokines. Notably, IL-4 induced significant
production ofIL-6 in a dose-dependent fashion when added to resting B cells. How-
ever, in contrast to several otherstimuli, IL-4 did not induce TNFa or TNF0 produc-
tion, implying a selective action of IL-4 on IL-6 induction.
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Reagents.
￿
F(aV)Z fragments of rabbit polyclonal antibodies to human g H chain (anti-IA;
Dako Corp., Copenhagen, Denmark) were prepared by pepsin treatment (7) and used at 75
14g/ml. The calcium ionophore ionomycin was purchased from Calbiochem-Behring Corp.
(LaJolla, CA) and used at a finalconcentration of0.5 1M. The phorbol esters tetradecanoyl-
phorboltacetat (TPA; Consolidated Midland Corp., Brewster, NY) and phorbol dibutyrate
(PDB; Sigma Chemical Co., Poole Dorset, UK) were both used at final concentrations of
10-s M. Human rIL-1-0 (kindly provided by Dr. A. Shaw, Glaxo Institute for Molecular
Biology, Geneva, Switzerland) had a specific activity of 5 x 107 U/ml. Human rIL-2 was
obtained from Cetus Corp. (Emeryville, CA). Human rIL-4 was purchased from Genzyme
(Boston, MA), and contained <5 ng LPS per ml IL-4 (i.e., per 20,000 U IL-4). As a source
of human IL-5, a supernatant from COS cells transfected with the gene for human IL-5 was
used (kindly provided by Dr. T. Honjo, Kyoto, Japan). Human rIL-6 had a specific activity
of 109 U/ml as determined in the B9 assay (8) and was kindly provided by Dr. L. Aarden,
University ofAmsterdam, The Netherlands. rIFN-y was a product from Genentech Inc. (South
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San Francisco, CA) kindly provided by G. R. Adolf at Ernst-Boehringer Institute for Ar-
zenimittelforschung (Vienna, Austria) with a specific activity of 1 .2 x 107 U/mg (bioassay,
inhibition of CPE and EMC virus on human carcinoma cells, A549). Human rTNFa and
human rTNF,8 (9, 10) were kindly provided from Genentech Inc., and had a specific activity
of 7 .6 x 107 and 10" U/mg protein for rTNFa and rTNF,Q, respectively.
Cell Purification and Culture.
￿
Highly enriched resting human B lymphocytes were isolated
from peripheral blood buffycoats by a method developed in our laboratory (Funderud, S.,
et al., manuscriptsubmitted for publication). Briefly, Dynabeads M450 (Dynal, Oslo, Norway)
were coated with the anti-CD19 mAb AB-1, and added to buffycoats at a ratio of five beads
per B cell, assuming 5 x 10' B cells per buffycoat. The mixture was incubated on a rocking
platform for 30 min at 4 °C, and cells forming rosettes with AB-I beads were trapped by a
samarium cobalt magnet (Dynal). Nonrosetting cells were subsequently removed by suction.
Rosetted cells were washed six times to remove nonrosetting cells. AB-1 beads will detach
from the B cells by overnight culture in RPMI 1640 (Gibco Laboratories, Paisley, Scotland)
supplemented with 1 % FCS. This procedure reads <0.5% T cells, 0.5 % monocytes, and 0.1 %
NK cells, as judged by indirect immunofluorescence staining (Funderud et al., manuscript
submitted for publication). In addition, the cells were subjected to two subsequent rounds
of purification. First, the highly enriched B Cells (106/ml) were exposed to Dynabeads M450
(Dynal) coated with antibodies against CD2 (Dakopatts, Copenhagen, Denmark), CD4 (Dy-
nabeads M450; no. 11106), CD8 (5C2; a kind gift of G. Gaudernack, Oslo, Norway), and
the panmonocyte antibody 1135 (kindly provided by G. Gaudernack). Finally, the cells were
incubated with OKM-1 (Ortho Diagnostic Systems Inc., Westwood, MA), OKT3 (Ortho
Diagnostic Systems Inc.), OKTII (Ortho Diagnostic Systems Inc.), anti-Leu-Ml (Becton Dick-
inson & Co., Sunnyvale, CA), and anti-NKHI (Coulter Immunology, Hialeah, FL) at saturating
conditions, followed by complement-dependent lysis using rabbit complement. The exten-
sively purified B cells contained <0.1o7o T cells, <0.1% monocytes, and <0.1% NK cells as
determinedby indirect immunofluorescence or immunoenzymatic stainings ofcytospin prepa-
rations.
Detection of TNF and IL-6 in Supernatants of Highly Purified B Cells.
￿
Purified B cells were
grown in RPMI 1640 (Gibco Laboratories) supplemented with penicillin, streptomycin and
1% FCS at a concentration of 106 cells/ml. Supernatants were collected at various time points
and assayed for cytokine levels in bioassays described below. TNF levels were determined
by the WEHI 164 clone 13 bioassay, which is capable of detecting as low as 0.1 pg/ml rTNFa
(11). To measure TNF0 activity, all TNFa activity was first neutralized by adding 10 EAg/ml
of a neutralizing mAb against TNFce for at least 30 min before bioassay. 200 ng ofthis mAb
(6H11) neutralizes at least 10 ng of rTNFa (T. Espevik, unpublished results). Neutralization
of TNFS activity in the test supernatants was done by adding rabbit polyclonal antibodies
against TNF0 (2.9 x 107 neutralizing U/ml; M. R. Shalaby, unpublished results).
Production of IL-6 was determined in a bioassay using the murine hybridoma cell line
B11.29 clone B9, which is dependent on IL-6 for growth (8, 12). rIL-1, rIL-2, rIL-4, and
rIL-5 had no detectable effects in the cytokine assays used.
Results
Effect ofIL-4 on IL-6 Productionfrom Purified Human B Cells.
￿
It is well established
that IL-4, when givento resting human B cells, promotes a marked increase in CD23
expression (2, 13), although it does not induce a regular Go-GI entry. It was there-
fore of interest to investigate the effects of IL-4 on cytokine production in human
B cells. As can be seen in Fig. 1, treatment of purified human peripheral blood B
lymphocytes with rIL-4 resulted in a marked, dose-dependent secretion ofIL-6. Even
a dose as low as 1 U/ml of IL-4 was sufficient to induce IL-6 production from purified
B cells. It is unlikely that this effect is due to the low amount of contaminating LPS
in the rIL-4 preparation, as LPS did not have any effects on IL-6 production in purified
B cellsover a wide dose range (data not shown). In another experiment, the kinetics
of IL-6 production from B cells stimulated with 50 U/ml IL-4 was examined . TheSMELAND ET AL.
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FIGURE 1 .
￿
IL-4 induction ofIL-6 secretion in humanB cells. Ex-
tensively purified restingB cells were stimulated with different con-
centrations of IL-4 for 48 h . The supernatants were assayed for
IL-6 activity asdescribed in MaterialsandMethods . Data repre-
sent mean (SD) oftriplicate measurements from a representative
experiment .
results in Fig. 2 show that IL-6 was detected in the supernatants already after 1-2 h,
reaching near maximal levels after 48 h of stimulation . The addition of rabbit
anti-human rIL-6 serum(W. Fiers, State University of Ghent, Belgium) at a 1 :120
dilution completely abolished the IL-6 activity in the test supernatants (data not
shown) . NoTNF activity was detected after IL-4 stimulation (Table I), indicating
that IL-4 is a specific inductor of IL-6 production in isolated B cells.
Effect of Cytokines and Phorbol Esters on IL-6 and TNF Production from Purified B
Cells. Both IL-1 and TNF-cx have been shown to induce IL-6 secretion in other
cell systems (3, 12). It was therefore of interest to explore the effects of cytokines
on TNF and IL-6 production in human B cells . However, neither rIL-1-/3, rIL-2,
rIL-5, rIL-6, rIFN-.y, rTNF-a, nor rTNF-0 induced IL-6 or TNF production in
B cells (Table I) . Phorbol esters like TPA andPDB activate resting B cells into GI
(14) and synergizewith anti-W or the calciumionophoreionomycinforBcell prolifer-
ation . Both TPA and PDB induced a markedly increased production of IL-6, as
well as TNF, especially when combined with ionomycin or anti-A . (Table I) . Max-
imal TNF levels were reached between 14 and 24 h after stimulation, while IL-6
induction tended to be more delayed with maximal levels most often found at 48 h
(data not shown) .
As treatment of resting B cells with polyclonal anti-A activates the cells into the
Gi phase of the cell cycle without marked S phase entry in the absence of cofactors
(7), we wanted to test the effects of anti-A on cytokine production . As can be seen
in Table I, polyclonal anti-/ .t alone induced only amodest increase in TNF and IL-6
secretion . However, anti-A . synergized with phorbol esters (Table I) and IL-4 (Fig .
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FIGURE 2 .
￿
Kinetics ofIL-4 induced IL-6 secretion
in human B cells . B cells were cultured for different
time periods in the presence ofIL-4 (50U/ml) . IL-6
activity was determined as described in Materials
and Methods .1466
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TABLE I
Production of TNF and IL-6 by Activated Human B Cells
Highly purified B cells were incubated with the indicated stimuli for 14 h (TNF) or 48 h (IL-6),
and the supernatants were assayed for cytokine activity as described in Materials and Methods .
The data represent mean (SD) oftriplicate measurements from two representative experiments .
3) forcytokine production . Thecombinationofanti-,uandIL-4 was almost as efficient
in inducing IL-6 production as the combination of ionomycin andPDB (data not
shown) .
ActivatedTlymphocytes have been shown to produceboth TNRtxas well asTNF-#
(15) . We therefore investigated the relative production of these two cytokines after
stimulation ofpurifiedBcells withPDB and ionomycin, whichrepresented the stimulus
FIGURE 3 .
￿
Synergistic action ofIL-4 and anti-1~ on
IL-6 production . Resting B cells were cultured with
anti-p (0), IL-4 (50 U/ml; ®), anti-,u plus IL-4(®),
or in medium alone (0) for the indicated time
periods. IL-6 activity was determined as described
in Materials and Methods.
Exp . 1
TNF
Exp . 2
pg/ml
Exp . 1
IL-6
Exp . 2
pg/ml
Control (medium) 0 .8 (0.05) 1 .6 (0.1) 10.8 (1 .7) 20.0 (1 .1)
Rabbit anti-,u 4.2 (0.9) 2.7 (0.7) 104.0 (3) 58.2 (8.3)
TPA 12.3 (0.8) 6 .7 (0.6) 51 .4 (9.0) 243.0 (29)
Rap, + TPA 52.0 (0.8) 16.3 (1 .0) 614.0 (56) 2,350.0 (444)
PDB 14.5 (1 .5) 6.6 (0 .5) 128.0 (15) 172.0 (12)
Ionomycin <0.4 0.6 (0.1) 14.1 (1 .6) 22.0 (3.4)
Ionomycin + TPA ND 28 .1 (3.8) ND 1,177.0 (95)
Ionomycin + PDB 70.0 (3.0) 86.0 (l3.5) 1,357.0 (55) >3,900.0
IL-1 (10 ng/ml) <0.4 1 .8 (0.1) 16.0 (3 .4) 28 .7 (2.3)
IL-1 (50 ng/ml) ND 2.0 (0.2) ND 8 .0 (0.6)
IL-2 (25 U/ml) <0.4 ND 10.0 (0 .4) ND
IL-4 (50 U/ml) <0.4 3.4 (0.1) 227.0 (8 .0) 550.0 (86)
IL-5 (l/1,000) 0 .7 (0.2) ND <10 ND
IL-6 (10 U/ml) 1 .1 (0.2) 1 .3 (0.1) 12.4 30.0 (2.0)
IL-6 (20 U/ml) ND 1.6 (0.1) ND 13.0 (0.4)
IL-6 (50 U/ml) ND 1 .6 (0.2) ND 36 .0 (0.1)
IFN-y (10 3 U/ml) 0.9 (0.02) ND 14.0 (2 .0) ND
TNF-a (l03 U/ml) ND 32 .5 (1 .4)
TNF-a (104 U/ml) <10 19 .9 (4.5)
TNF-ß (103 U/ml) ND 23.3 (3.0)
TNF-ß (104 U/ml) ND 22.9 (2.1)SMELAND ET AL.
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that induced the highest levels of total TNF production (Table I). In different ex-
periments, between 44 and 80% ofthe TNF activity detected after 48 h ofculture
wasdue to presence ofTNFa (data not shown). Moreover, our results indicate that
TNFa production precedes TNF/3 production in activated B cells(data notshown).
Discussion
In this report we have examined the production ofTNF and IL-6 in peripheral
blood B cells. As severalcell types present inperipheral bloodare capable ofsecreting
these cytokines, it was important to use extensively purified B cells in order to mini-
mize possible effects ofcontaminating cells. Before use, the cells had therefore been
subjected to several rounds ofpurification by using positive and negative selection
with immunomagnetic beads followed by complement-mediated lysis. The results
demonstrate that rIL-4 induced a marked secretion ofIL-6 in resting B cells, and
that anti-u significantly potentiated the IL-4-induced IL-6 production. In contrast
to findings in other cell systems, such as fibroblasts and endothelial cells (3, 12),
rIL-1 and rTNFa did not induce any significant IL-6 secretion. The selectivity of
the IL-4 effect on IL-6 production is further strengthened by the observation that
IL-4 did not induce the B cells to produce TNF. None ofthe other cytokines tested
were able to induce IL-6 production when given to resting B cells. This accords
well with databy DeFrance et al. (13), who found that ofseveral factors tested, only
IL-4 induced increased CD23 expression in human B cells.
Our results also confirmthe recent observations that activatedhuman B cells pro-
duce TNFa and TNF0 (5), as well as IL-6 (6). Phorbol esters, in particular, seem
to be very potent in inducing cytokine secretion in human B cells, especially when
combined with ionomycin. However, it is clear that the observed secretion ofTNF
and IL-6 is not a mere result ofcellular activation, as polyclonal anti-,U, which acti-
vates resting B cells into the G, phase ofthe cell cycle (7), only induced a modestly
increased secretion of these cytokines when given alone.
TNFa, TNF/3, and IL-6 have all been shown to influence functional responses
of B cells (1-3). Available data therefore suggest that B cells may produce and re-
spond to important cytokines, adding to the complexity ofthe regulation of B cell
responses. Furthermore, our finding that IL-4 induces IL-6 production raises the
possibility that the induction of IgG secretion in human B cells by IL-4, at least
partly, may bedue to an autocrine production ofIL-6. This emphasizes the difficul-
ties in assessing the effects of a single cytokine given the extensive interaction of
cytokines in complex networks.
Summary
In this paper we have shown that extensively purified human B lymphocytes re-
spond to IL-4treatmentwith amarked production ofIL-6. Addition ofanti-1Apoten-
tiated the effect ofIL-4 on IL-6 production. Other cytokines tested like TNFa and
-a, IFN-y, IL-1, IL-2, andIL-5 did not induce IL-6 secretion when givento resting
B cells. Although B cells generally also produced TNFa andTNF0 upon stimula-
tion, IL-4 did not induce TNFsecretion and seeminglyhada specific effect on IL-6
production.
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